Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

StockNews.com started coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report published on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ BCLI opened at $1.73 on Friday. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.89. The company has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $2.55. The firm has a market capitalization of $9.87 million, a PE ratio of -0.36 and a beta of 0.26.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.